Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19

Abstract
Pediatric COVID-19 following SARS-CoV-2 infection is associated with fewer hospitalizations and often milder disease than in adults. A subset of children, however, present with Multisystem Inflammatory Syndrome in Children (MIS-C) that can lead to vascular complications and shock, but rarely death. The immune features of MIS-C compared to pediatric COVID-19 or adult disease remain poorly understood. We analyzed peripheral blood immune responses in hospitalized SARS-CoV-2 infected pediatric patients (pediatric COVID-19) and patients with MIS-C. MIS-C patients had patterns of T cell-biased lymphopenia and T cell activation similar to severely ill adults, and all patients with MIS-C had SARS-CoV-2 spike-specific antibodies at admission. A distinct feature of MIS-C patients was robust activation of vascular patrolling CX3CR1+ CD8+ T cells that correlated with the use of vasoactive medication. Finally, whereas pediatric COVID-19 patients with acute respiratory distress syndrome (ARDS) had sustained immune activation, MIS-C patients displayed clinical improvement over time, concomitant with decreasing immune activation. Thus, non-MIS-C versus MIS-C SARS-CoV-2 associated illnesses are characterized by divergent immune signatures that are temporally distinct from one another and implicate CD8+ T cells in the clinical presentation and trajectory of MIS-C.
Funding Information
  • National Institutes of Health (K08 AI136660)
  • National Institutes of Health (AI105343)
  • National Institutes of Health (AI082630)
  • National Institutes of Health (HL137006)
  • National Institutes of Health (HL137915)
  • National Institutes of Health (CA230157)
  • National Institutes of Health (R01CA193776)
  • National Institutes of Health (CA234842)
  • National Heart, Lung, and Blood Institute (HL137006)
  • National Heart, Lung, and Blood Institute (HL13791)
  • National Institutes of Health (T32-AI-007324)
  • National Institutes of Health (R01AI121250)
  • National Institute of Allergy and Infectious Diseases (AI105343)
  • National Cancer Institute (CA009140)
  • National Institutes of Health (T32 CA009140)
  • National Institutes of Health (HL143613)
  • National Institutes of Health (T32 CA009140)
  • National Institute of Allergy and Infectious Diseases (K08 AI136660)
  • The Parker Foundation
  • Mark Foundation For Cancer Research
  • University of Pennsylvania Institute for Immunology Glick (COVID-19)
  • Paul G. Allen Frontiers Group
  • Children's Hospital of Philadelphia
  • Elektrobit
  • Högskolan i Borås
  • Classical Association
  • Parker Institute for Cancer Immunotherapy
  • National Institute of Allergy and Infectious Diseases (AI08263)